S
Sivaraman Jayanthi
Researcher at VIT University
Publications - 37
Citations - 317
Sivaraman Jayanthi is an academic researcher from VIT University. The author has contributed to research in topics: Docking (molecular) & Virtual screening. The author has an hindex of 8, co-authored 33 publications receiving 208 citations. Previous affiliations of Sivaraman Jayanthi include PSG College of Technology.
Papers
More filters
Journal ArticleDOI
Quercetin-3-O-rhamnoside from Euphorbia hirta protects against snake Venom induced toxicity.
Kadiyala Gopi,K. Anbarasu,Kadali Renu,Sivaraman Jayanthi,Bannikuppe S. Vishwanath,Gurunathan Jayaraman +5 more
TL;DR: For the first time Quercetin-3-O-α-rhamnoside, isolated from E. hirta, has been shown to exhibit anti-snake venom activity against Naja naja venom induced toxicity.
Journal ArticleDOI
Potent and highly selective dual-targeting monoamine oxidase-B inhibitors: Fluorinated chalcones of morpholine versus imidazole.
Bijo Mathew,Seung Cheol Baek,Della Grace Thomas Parambi,Jae P Lee,Githa Elizabeth Mathew,Sivaraman Jayanthi,D. Vinod,Clariya Rapheal,Vinod Devikrishna,Shahin Shad Kondarath,Sahab Uddin,Hoon Kim +11 more
TL;DR: The results indicate that morpholine containing chalcones are highly selective MAO‐B inhibitors having reversibility properties and exhibit good blood–brain barrier permeation in the PAMPA method.
Journal ArticleDOI
Control of size and antimicrobial activity of green synthesized silver nanoparticles
TL;DR: In this article, a unique way to control the size and antibacterial activities of silver nanoparticles (Ag NPs) using three different leaf conditions (fresh, oven-dried and sundried) of Alstonia scholaris was reported.
Journal ArticleDOI
Partial characterization and anticancer activities of purified glycoprotein extracted from green seaweed Codium decorticatum
TL;DR: Analysis of anticancer potential of this GLP revealed a remarkable inhibition of cell growth in breast, cervical and lung cancer cells.
Journal ArticleDOI
Identification of curcumin derivatives as human LMTK3 inhibitors for breast cancer: a docking, dynamics, and MM/PBSA approach.
K. Anbarasu,Sivaraman Jayanthi +1 more
TL;DR: Novel LMTK3 inhibitors tetrahydrocurcumin, curcumin 4,4′-diacetate, and demethoxycurcumin have been proposed with inhibition mechanism to prove its role in breast cancer therapeutics.